CLINICAL TRIALS PROFILE FOR XOLEGEL
✉ Email this page to a colleague
All Clinical Trials for XOLEGEL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00536991 ↗ | Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer | Terminated | National Cancer Institute (NCI) | Phase 1/Phase 2 | 2006-10-01 | This phase I/II trial studies the side effects and best dose of calcitriol when given in combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in treating patients with prostate cancer. Calcitriol may help prostate cancer cells become more like normal cells and grow and spread more slowly. Ketoconazole and therapeutic hydrocortisone may help calcitriol work better by making tumor cells more sensitive to the drug. Giving calcitriol together with ketoconazole and therapeutic hydrocortisone may be a better treatment for prostate cancer. |
| NCT00536991 ↗ | Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer | Terminated | Roswell Park Cancer Institute | Phase 1/Phase 2 | 2006-10-01 | This phase I/II trial studies the side effects and best dose of calcitriol when given in combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in treating patients with prostate cancer. Calcitriol may help prostate cancer cells become more like normal cells and grow and spread more slowly. Ketoconazole and therapeutic hydrocortisone may help calcitriol work better by making tumor cells more sensitive to the drug. Giving calcitriol together with ketoconazole and therapeutic hydrocortisone may be a better treatment for prostate cancer. |
| NCT03471364 ↗ | Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash | Recruiting | National Cancer Institute (NCI) | Early Phase 1 | 2018-08-22 | This early phase I trial studies the side effects of ketoconazole and how well it works in treating participants with ongoing EGFR inhibitor-induced rash. Ketoconazole may reduce the symptoms related to EGFR inhibitor therapy and improve EGFR inhibitor-induced rash. |
| NCT03471364 ↗ | Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash | Recruiting | Mayo Clinic | Early Phase 1 | 2018-08-22 | This early phase I trial studies the side effects of ketoconazole and how well it works in treating participants with ongoing EGFR inhibitor-induced rash. Ketoconazole may reduce the symptoms related to EGFR inhibitor therapy and improve EGFR inhibitor-induced rash. |
| NCT03796273 ↗ | Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases | Recruiting | National Cancer Institute (NCI) | Early Phase 1 | 2019-03-13 | This trial studies the side effects and how well ketoconazole works before surgery in treating patients with glioma that has come back or breast cancer that has spread to the brain. Ketoconazole is an antifungal drug that may be able to block a protein, tGLI1 and may help to treat brain tumors. |
| NCT03796273 ↗ | Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases | Recruiting | Wake Forest University Health Sciences | Early Phase 1 | 2019-03-13 | This trial studies the side effects and how well ketoconazole works before surgery in treating patients with glioma that has come back or breast cancer that has spread to the brain. Ketoconazole is an antifungal drug that may be able to block a protein, tGLI1 and may help to treat brain tumors. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for XOLEGEL
Condition Name
Clinical Trial Locations for XOLEGEL
Trials by Country
Clinical Trial Progress for XOLEGEL
Clinical Trial Phase
Clinical Trial Sponsors for XOLEGEL
Sponsor Name
